Grant✓ Small businesses may apply
NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)
National Institutes of Health
- Opportunity #
- PAR-24-269
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.279
- Status
- posted
- Posted
- Aug 13, 2024
- Closes
- Feb 11, 2027
- Funding instrument
- Cooperative Agreement
- Category
- Education, Health
- Cost sharing required
- No
Who can apply
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •Public and State controlled institutions of higher education
- •County governments
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •State governments
- •City or township governments
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •Private institutions of higher education
- •For profit organizations other than small businesses
- •Public housing authorities/Indian housing authorities
- •Special district governments
- •Small businesses
- •Native American tribal governments (Federally recognized)
- •Independent school districts
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Synopsis
The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorders (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotypes and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications may examine any type of genomic variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. Other areas of interest include genomics analysis at the circuit level and the application of neuroscience to genomics studies. NIDA expects these studies to uncover novel mechanisms that contribute to various stages across the SUD trajectory and inform future studies about potential targets and therapeutic strategies for addiction.
Contact
National Institutes of Health · grantsinfo@nih.gov